Prodrome Sciences Inc.; Chiba University Hospital, Division of Clinical Mass Spectrometry; Chiba Cancer Center; and Chiba Foundation for Health Promotion & Disease Prevention have completed year two of a three-year collaboration comparing the clinical mass spectrometric analysis of serum GTAs (gastrointestinal tract acids) and FIT (fecal immunohistochemical) tests for identifying persons with increased risk of colorectal cancer.
As part of the collaboration, the Chiba Health Foundation collects blood and fecal samples from individuals undergoing colorectal cancer screening. Prodrome Sciences measures serum GTA levels using its high-throughput, high-resolution, accurate-mass technology and the Chiba Health Foundation performs FIT analyses.
Over 3,000 participants have already participated in the program. The three-year study began in 2017 and will conclude in 2019. The goals of the research collaboration are to compare FIT and GTA tests when used independently and together to maximize the efficiency of colorectal cancer screening and to advance the use of Prodrome Sciences’ technology for routine procedures such as colorectal cancer screening in Japan.